Understanding how drugs are delivered to diseased tissue, and their subsequent spatial and temporal distribution, is a key factor in the development of effective, targeted therapies.
Introduction
Mathematical modelling of biological tissue is increasingly used to better understand complex biological phenomena, and to better understand the development of disease. 1 This developing paradigm of computational experiments enables complex and subtle interventions can be performed in a manner that would be challenging or imposible in a conventional experimental setting. Multiple hypotheses can be iteratively generated and tested, allowing new research avenues to be discovered, and for them to be rapidly and cheaply evaluated, at scale.
In this study we present a novel framework for performing realistic computational experiments that naturally incorporates the variability and heterogeneity found between biological samples (even those derived from the same disease process). It allows large tissue samples to be imaged and treated as living specimens, by combining cutting-edge optical imaging techniques with mathematical modelling. We have named our framework REANIMATE (REAlistic Numerical Image-based Modelling of biologicAl Tissue substratEs) (see
Figure 1).
For the results generated by computational experiments to be confidently accepted, careful experimental validation must be performed. Through its use of optical image data from cleared (transparent) tissue, REANIMATE can be used to perform computational experiments on realistic, large, 2 high resolution structural data, rather than relying on small, isolated samples or synthetically-generated substrates. Optical imaging of cleared tissue can provide spatial data on complex, interacting structures (such as blood vessel networks, cell nuclei, etc.), which can be explored, across entire organs, 3, 4 and at resolutions of a few microns, 2 by Figure 1 . The REANIMATE pipeline for in vivo and ex vivo imaging of intact tumours and performing three-dimensional computational fluid mechanics simulations. After in vivo imaging (1) , which can be performed longitudinally during tumor growth, tumours are resected and optically cleared (2) , to render tumours transparent for three-dimensional fluorescence imaging. Optical images are processed to segment fluorescently-labelled structures within the tumor microenvironment (3) (in this case, blood vessel networks), which are reconstructed in 3D graph format (nodes and connecting segments, each with a radius corresponding to the size of the blood vessel). These geometrical data become the substrate for computational fluid dynamic models to estimate steady-state blood flow and interstitial transport (4) and time-dependent numerical modelling of drug delivery (5) . All of these data can then be used to perform in silico experiments (e.g. assessing the heterogeneous delivery of drugs or contrast agents), which can be compared with in vivo experiments in the same tumor models, or even the same mice. In this study, REANIMATE is used to study the action of a vascular disrupting agent (Oxi4503) in two models of human colorectal carcinoma.
This complex physiological-pharmacological landscape requires careful analysis in order to be fully understood, and is most appropriately and naturally approached within a mathematical modelling framework. The numerical modelling component of REANIMATE consists of two steps: first, a solution is sought from a set of coupled fluid dynamics models that describe steady-state vascular and interstitial fluid transport; second, the steady-state solution (or set of solutions) is used to parameterise a time-dependent model that describes the vascular and interstitial uptake of exogenousy administered material. This can be used, for example, to model the heterogenous pharmacokinetics of drug or imaging contrast agents, or delivery of individual particles (e.g. T-cells, antibodies). Terms can also be introduced to describe drug targetting and metabolism.
As a first evaluation, we have used REANIMATE to: 1) study the spatially heterogeneous uptake of a gadolinium-based MRI compound (which allowed us to compare nuerical modelling solutions with ground-truth in vivo data); and 2) investigate the effect of the vascular disrupting agent (VDA) Oxi4503 on tumour vasculature. These results provided a rich, three-dimensional framework for probing spatially heterogeneous tumour drug delivery and treatment response.
Results

Preparation of tissue substrates for mathematical modelling from optically-cleared tissue samples
SW1222 and LS174T human colorectal carcinoma tumours have been extensively studied, by our group and others, with SW1222 tumors displaying greater cell differentiation, more uniform vasculature and greater perfusion than LS174T tumors. [9] [10] [11] [12] [13] [14] [15] These tumours formed the basis of our initial evaluation of the REANIMATE framework. Mice bearing each tumour type (n=5 of each) were grown subcutaneously, for 10 to 14 days, to a mean volume of 83 ± 12 mm 3 . These mice were injected intravenously with fluorescently-labelled lectin (AlexaFluor-647) and, following a circulation time of 5 minutes, tumors were resected, optically cleared with BABB, and imaged with optical projection tomography (OPT) 16 .
Blood vessels were segmented from OPT images using Frangi filtering 17 and thresholding, then converted into graph format, consisting of nodes (branch points) and vessel segments.
These networks were typically composed of 30,000 to 200,000 nodes (Figure 2a ). We performed a comparison of the vessel architecture from each tumor type with previously published data, which showed that vessel architecture was preserved during tissue clearing (see Supplemental Materials). 
REANIMATE simulation of steady-state tumor blood flow and tissue perfusion
Our first aim was to use these whole-tumor blood vessel networks as the substrate for novel simulations of steady-state, whole-tumor fluid dynamics. Our steady-state mathematical model of tumour fluid dynamics was comprised of coupled intravascular and interstitial compartments, with exchange mediated by vascular permeability. Blood flow and interstitial delivery were modelled using Poiseille flow and Fick's law, respectively, and we optimised our steady-state model over the entire tumor by assigning semi-stochastic pressure boundary conditions to inlet vessels. We performed our initial simulations on six colorectal tumor xenografts (n=3 SW1222 and n=3 LS174T).
Solutions to our mathematical model predicted significant differences in blood flow, blood velocity and vessel wall sheer stress, between the SW1222 and LS174T tumour types, which is consistent with their known characteristics (see Figure 3 , Table 1 ). Key to the interpretation of these results was our ability to compare them directly with equivalent in vivo imaging data (in this case arterial spin labelling magnetic resonance imaging (ASL MRI)), which can be used to quantify perfusion, noninvasively 9 . Perfusion is a measure of the rate of delivery of fluid to biological tissue, and is dependent on blood flow, vascular permeability and interstitial density, amongst other factors. We regridded simulated perfusion values to the resolution of in vivo images (150 µm) for direct comparison. Both in vivo measurements and simulations showed that SW1222 tumours were better perfused than LS174T tumors, which is again consistent with the results of previous studies. 18 We found that, in both in vivo measurements and simulations, perfusion was distributed heterogeneously throughout the tumors, with markedly raised values at the periphery of both tumor types; however, perfusion at the centre of SW1222 tumors was much greater than in LS174T tumors, both in simulations and in vivo data (Figure 2b, c and d ).
These results show that mathematical modelling of fluid dynamics, using cleared tumor tissue as a substrate, is both feasible and provides quantitative predictions of vascular perfusion that are in keeping with experimental results. Our next step was to use the steady-state to parameterise a time-dependent model to simulate the delivery of exogenously-administered material.
REANIMATE simulation of MRI contrast agent (Gd-DTPA) delivery
As a first evaluation, we chose to model the dynamics of chelated gadolinium (Gd-DTPA), a widely used MRI contrast agent with well-studied pharmacokinetics, and directly compare them with in vivo measurements. Gd-DTPA can be thought of as a proxy for a non-metabolised therapeutic agent. Time-dependent simulations were calculated using a 'propagating front' algorithm, that used steady-state solutions to mimic the physical delivery of material, both via vascular flow and by endothelial and interstitial diffusion.
To provide ground-truth data for comparison, and to generate new modelling substrates, we performed in vivo experiments to measure the delivery of a bolus of Gd-DTPA in a set of LS174T (n=5) and SW1222 (n=6) tumours, using a dynamic contrast-enhanced (DCE) MRI sequence ( Figure 3 ). Following these measurements, mice were culled via cervical dislocation.
We resected and set two tumours aside (one LS174T and one SW1222) for processing within the REANIMATE framework.
Here, steady-state simulations were performed as described above, and were used as the basis for time-dependent delivery simulations. The influence of each vessel network inlet was modelled independently, and an algorithm was developed that monitored a propagating front through the network. Exchange between the vascular and interstitium was cast in a finite element framework, with vessel permeability initially fixed at 1×10 -6 cm s ). Both in vivo measurements and simulations had a duration of 12 minutes, with a temporal resolution of 16 seconds.
Simulations were driven by a bi-exponential vascular input function, taken from the literature. 24 Initially, 1% of the entire dose of the input function was partitioned across all tumor inlets, weighted by the inflow rate for the individual inlet.
Intravascular and interstitial delivery were rendered as four-dimensional visualisations (see
Supplemental Movie 1 and Supplemental Move 2). Analysis of our experimental MRI
measurements from LS174T tumors revealed a prolonged, peripheral enhancement pattern, which is typical of the tumor type 18 (Figure 3a) . Plotting contrast agent uptake as a function of distance from the tumor edge revealed a highly heterogeneous enhancement pattern, with decreasing concentration for increasing proximity to the tumour centre (Figure 3b ).
Conversely, we found that SW1222 tumors enhanced with Gd-DTPA much more rapidly and homogeneously, with a peak enhancement at around 4 minutes, followed by a washout phase. We fitted our experimental Gd-DTPA concentration-time curves to a phenomenological model of contrast agent enhancement (Equ. 14), in which the parameter S0 defines the peak enhancement, and r1 and r2 are rates of concentration increase and decrease, respectively. 25 Again, plotting these parameters as a function of distance from the edge of each tumor type (Figure 3c ) confirmed our observations of decreasing contrast uptake with distance from the tumor edge in LS174T tumors, compared with a more homogeneous enhancement pattern in SW1222 tumors. We can therefore conclude from these experiments that REANIMATE can provide good orderof-magnitude estimates of the delivery of Gd-DTPA, but which can be further finessed by in vivo measurements.
Iterative optimisation of time-dependent delivery simulations guided by experimental results
REANIMATE solutions describing
Dual-fluorophore optical imaging of Oxi4503 response
Using our optimised Gd-DTPA delivery data, we then went on to investigate the ability of REANIMATE to model drug uptake and response to treatment. This required the development of a novel dual-fluorophore imaging technique that allowed measurements of tumor vascular structure at two separate time points to be encoded. We chose to model vascular targeting therapy, due to its rapid, well-characterised mechanism of action, which can be captured with in vivo MRI 26 . The acute effects of VDAs have been well-documented, using histology, 27,28 MRI 29 and in vivo confocal microscopy, 30 which demonstrate rapid vascular shutdown and extensive vessel fragmentation within the first 60 minutes to 24 hours of administration. This causes decreased perfusion, especially in the central part of the tumour, 29, 31 and an associated increase in hypoxia and cell death. 31 In this study, we investigated a single dose of Oxi4503, at 40 mg kg -1 .
Our dual-fluorophore method allowed us to characterise blood vessel structure at two separate time points, by administering fluorescently-labelled lectin (AlexaFluor-568) just prior to injecting Oxi4503, and then a second lectin 90 minutes later (AlexaFluor-647). Our rationale was that vessels occluded by Oxi4503, and were no longer perfused, would be labelled by only the first fluorophore; vessels that remained perfused following therapy would be labelled with both fluorophores. As a validation of our results, in vivo arterial spin labelling (ASL) MRI was also performed on a subset of tumors (n=3 of each tumor type). Mice, each bearing an LS174T or SW1222 tumor, were randomly assigned to treatment (Oxi4503, 40 mg kg These results show that, alongside realistic predictions from steady-state fluid dynamics simulations and Gd-DTPA uptake, REANIMATE can also provide realistic predictions of the response to the vascular targeting agent Oxi4503. 
Treatment-focussed hypothesis generation and testing with REANIMATE
We lastly used REANIMATE to test two hypotheses: 1) that vessels that receive the greatest Oxi4503 exposure are more likely to become non-perfused; 2) that network geometry differences between tumor types could influence their response to VDA therapy.
To test the first hypothesis, we compared vessels from our dual-labelled datasets that had lost perfusion post-Oxi4503 (i.e. were labelled with just one fluorphore), with their simulated exposure to Oxi4503, as predicted by REANIMATE. The result of this analysis was the opposite to that expected: that non-perfused vessels exhibited a signficantly lower simulated exposure than vessels that remained perfused (2.0 compared with 3.8 mM min m -2 (p<0.001)) ( Figure   6c ). This contradicts our first hypothesis, that perfusion loss would be associated with greater Oxi4503 dose, so was rejected. This lead us to next evaluate our second hypothesis, and investigate differences in the vascular architecture of the two tumour types. In particular, we evaluated the functional connectivity of the two tumor types. 
Discussion
We have presented REANIMATE, a novel, large-scale, three-dimensional imaging, modelling and analysis framework. REANIMATE uses advances in optical imaging of cleared tissue 16, 33, 34 to produce realistic substrates for computational modelling, and is guided by in vivo imaging data. We applied REANIMATE to imaging data from two murine models of colorectal cancer to simulate: 1) steady-state fluid dynamics (blood flow, intravascular and interstitial fluid pressure); 2) uptake of the MRI contrast agent Gd-DTPA; and 3) uptake and response to vascular-targeting treatment (Oxi4503). Our results demonstrate the feasibility and accuracy of this novel, whole-tissue approach to numerical modelling, which allows computational (in silico) experiments to be performed on real-world tumours.
Computational modelling of cancer has a relatively long history, [35] [36] [37] [38] and has allowed us to develop our understanding of, for example, tumour angiogenesis and microenvironmental structure in response to therapy, such as tumour blood flow, 39 oxygen transport 40 and VEGF distribution. 41 REANIMATE builds on and extends this work by including simulation substrates from complete, real-world tumors, in three spatial dimensions, which are guided by and compared against in vivo measurements. In this initial demonstration, we focussed on the vasculature of colorectal xenograft models, which we imaged by labelling with fluorescent lectin. This allowed blood flow to be explicitly simulated in realistic networks, providing new insights into drug delivery and blood flow heterogeneity. We treated the interstitium as a continuum, but future analyses could include additional structural elements such as cell membranes and nuclei, by multifluorescence labelling. Indeed, there is significant potential for extending and enhancing REANIMATE in other pathologies, to allow more in-depth computational experiments to be performed.
When we compared our REANIMATE predictions with in vivo imaging data, we found a good correspondence with the magnitude and spatial heterogeneity of in vivo measurements, both in steady-state and time-dependent simulation parameters. Perfusion was predicted to be signficantly greater in SW1222 tumors than in LS174T tumors, which reflects the results of in vivo arterial spin labelling measurements, and was highly heterogenous, with flow concentrated at the periphery of both tumor types. Conversely, Gd-DTPA uptake was more heterogeneous in LS174T than in SW1222 tumors, both in in vivo MRI measurements and simulations (with minimal parameter optimisation).
We focussed here on drug delivery, but REANIMATE could easily be modified to include response to therapy, for example by reducing interstitial cell density to reflect response to a cytotoxic agent. Tumors are normally spatially heterogeneous, and we have shown here that adding realistic, whole-tumour microstructure allows accurate predictions for drug delivery and tumor pathophysiology to be made. We showed that structural connectivity and Importantly, these results demonstrate a mechanism through which tumors can exhibit a form of physical resistance to drug therapies, which manifests via complex interactions across large regions within a tumor, or across whole organs. We have previously observed a similar heterogeneous response when assessing the response of colorectal metastases in the liver, in which 9 the magnitude of the response decreased with increasing distance of individual tumors from major blood vessels. This is again indicative of treatment resistance via physical mechanisms, such as vascular geometry and poor blood flow.
The detailed insights generated in this study could not have been made with conventional two-dimensional analysis of histological sections, or in vivo experiments that lack the spatial resolution and functional information to access this information, and demonstrates a key strength of the REANIMATE approach. We anticipate that REANIMATE will enable us to study and understand complex interactions between biological phenomena, allowing new insights into key challenges in cancer research. This could include a better understanding of limitations in tumor drug delivery (and how this can be mediated) 36, 42 and the development of resistance to therapy via physical (rather than biochemical) mechanisms.
Materials and Methods
Tumour xenograft models
All 
Fluorescent labelling of tumour vasculature and perfusion fixation
Lectin (griffonia simplicifolia) bound to either Alexa-647 (Thermo Fisher Scientific, L32451) or Alexa-568 (Thermo Fisher Scientific, L32458) was injected intravenously (i.v.) and allowed to circulate for 5 minutes, prior to perfuse fixation, to allow sufficient binding to the vascular endothelium. 3 To prevent blood clot formation within the vasculature, mice were individually heparinized (Wockhardt) by intraperitoneal (i.p.) injection (0.2 ml, with 1000 IU ml -1 ). Mice were terminally anaesthetized by i.p. injection of 100 mg kg -1 sodium pentobarbital (Animalcare, Pentoject) diluted in 0.1 ml phosphate buffered saline (PBS). Once anaesthesia was confirmed, surgical procedures for intracardial perfusion were performed for systemic clearance of blood. PBS (30 ml, maintained at 37 °C) was administered with a perfusion pump (Watson Marlow, 5058)
at a flow rate of 3 ml/min to mimic normal blood flow. After the complete drainage of blood, 40 ml of 4% paraformaldehyde (PFA, VWR chemicals) was administered. Harvested tumours were stored for 12 hours in 4% PFA (10 ml total volume, at 4 °C).
Treatment with Oxi4503
Following 10 to 14 days of growth, mice were randomly assigned to treatment (Oxi4503, n=6) and control (saline) groups, with n=3 SW122 and n=3 LS174T in each. Treated groups were injected i.v. with 100 µg lectin-AlexFluor 647 diluted in sterile saline at neutral pH (100 µl) containing 1 mM CaCl2, followed by administration of OXi4503 (40 mg kg -1 , 4 mg ml -1 ). Control mice were injected with 100 µl saline. After 2 hours, all mice were injected i.v. with 100 µg lectin-AlexFluor 568 diluted in sterile saline at neutral pH (100 µl) containing 1 mM CaCl2. 5 minutes after injection mice were culled and underwent perfuse-fixation, as described above.
Optical clearing and imaging
Following perfuse-fixation, tumours were rinsed three times in PBS, for 10 minutes each, prior to clearing, to remove residual formaldehyde and avoid over-fixation. 45 After PBS rinsing, harvested tumours were optically cleared with BABB (1:2 benzyl alcohol: benzyl benzoate).
Our BABB clearing preparation consisted of dehydration in methanol for 48 hours followed by emersion in BABB for 48 hours. 
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OPT data were reconstructed with Nrecon (Bruker, Ettlingen, Germany). Misalignment compensation was used to correct misalignment during projection image acquisition, in order to reduce tails, doubling or blurring in the reconstructed image. Depth of correction for ring artifact reduction was 4 and defect pixel masking was 50% for all scans.
Image processing and vessel segmentation
Reconstructed OPT data were used to generate whole-tumor blood vessel networks. First, a three-dimensional Gaussian filter with a width of 50 pixels (corresponding to a physical size of 300 µm, greater than the largest vessel diameter) was applied. The filtered data were subtracted from the original data to remove background variations in autofluorescence. A three-dimensional Frangi filter was then applied (Matlab, MathWorks, Natick, MA) to enhance vessel-like structures. 17 The response to the filter was thresholded to segment blood vessels from background. Skeletonisation of these thresholded data was performed in Amira (Thermo Fisher Scientific, Hillsboro, OR), which also converted the data into graph format (i.e. nodes and segments with associated radii). To ensure that vessel structures were accurately represented, 2D sections from the original image data were swept through reconstructed 3D networks (in Amira), with visual inspection used to for an accordance between vessel location and thickness, and the location of fluorescence signal (see Supplemental Figure 2 ).
Mathematical model of steady-state tissue fluid dynamics
Blood flow through the segmented vascular network was modelled by Poiseuille's law, using empirically-derived laws for blood viscosity (assuming constant network haematocrit) and following the established approach developed in 47, 48 . This model assumes conservation of flux at vessel junctions to define a linear system to solve for the pressures at nodal points in the network (from which vessel fluxes are calculated using Poiseuille). Boundary conditions on terminal nodes in the network were estimated using the optimisation method of Fry et al., 49 which matches the network solution to target mean shear stress and pressure values.
The approach of Fry et al. 49 requires a proportion of boundary conditions to be applied to a microvascular network. However, neither flow or pressure measurements were obtained in vivo for our tumour networks. As such, a stochastic procedure was employed to induce a arbitrary pressure drop (55 to 15 mmHg for both LS147T and SW1222 simulations) across a network. 50 In addition, consistent with previous studies, 51, 52 33% of internal nodes were assigned zero flow. All remaining boundary nodes were unknowns. This procedure ensured physiologically realistic tissue perfusion when compared to that gathered in vivo using ASL MRI.
The network flow solution was coupled to an interstitial fluid transport model, adapting the approach taken in Secomb et al. 53 to model oxygen delivery to tissue. The interstitium is modelled as a porous medium using Darcy's law,
with ∇ · u = 0 and subject to p  pI as x  ∞. Here, u is the volume-averaged interstitial blood velocity (IFV), p is the interstitial fluid pressure (IFP), pI is the target IFP, and κ is the conductance of the interstitial tissue. Starling's law is used to describe fluid transport across the endothelium, from the vessels into the interstitium:
where, q is the fluid flux across the endothelium, Lp is the hydraulic conductance of the vessel wall, S is the surface area of the vasculature, V is the tissue, σ is the oncotic reflection coefficient and, Δp and ΔΠ fluid and oncotic pressure gradients between the vasculature and tissue.
To solve the model computationally, we discretised the tumor vasculature into a series of N sources of strength qsj so that the conservation of mass equation is modified to
where xj and qsj are the spatial coordinates and (unknown) strength at xj of source j, 
Mathematical model of time-dependent vascular and interstitial transport
A 'propagating front' (PF) algorithm was developed to describe the transport of solute (e.g. a 
where Cj(t) is the concentration in each inflowing vessel segment. Within vessel segments, vascular permeability to drug transport was modelled according to
where S is the internal surface area of the vessel, is the vessel wall permeability and Q is the blood flow (Poiseuille). was initially fixed at 10 -4 m s -1
. 19, 20 Interstitial delivery was cast in a forward finite difference framework, in which vessels were considered as one-dimensional emitters. Points were gridded on concentric cylinders, regularly spaced around the vessel segment (with spacing ranging from 10 to 100 µm). Exchange of the drug across the vessel wall and diffusion through the interstitium were modelled as
where , +1 is the interstitial concentration at the j th time point and is the vascular = ℎ 2 [13] D is the diffusion coefficient of the agent under investigation. Following each finite difference step, interstitial diffusion solutions were regridded to a course 64×64×64 matrix (approximately 100 µm isotropic resolution) for storage. During regridding, absolute numbers of moles were converted to molar concentration.
Measurement of vessel network functional connectivity and redundancy
The mean number of viable alternative pathways, N, for each node if the shortest path (based on transit time -i.e. incorporating flow velocity) was occluded was used to define the redundancy of tumor vessel networks, alongside r, the average additional distance that would be travelled. 54 Connectivity was defined as the sum of the number of nodes upstream and the number of nodes downstream of a given node, divided by the total number of nodes in the network. All three measures reflect functional connectivity (i.e. following pathways with decreasing vascular pressure from steady-state fluid dynamics simulations), and were estimated from vessel networks using algorithms written in-house in Python 2.7.
Simulation of Gd-DTPA delivery
The systemic pharmacokinetics for Gd-DTPA in mice, following an i.v. bolus injection, were modelled as a biexponential decay: .
Dynamic contrast-enhanced MRI
Gadolinium-DTPA (Magnevist, Bayer, Leverkusen, Germany) was injected as a bolus into mouse tail veins, using a power injector (Harvard Instruments, Cambourne, UK). We injected 5 mL kg -1 over a period of 5 seconds, which was initiated at 90 seconds after the start of a dynamic, spoiled gradient-echo sequence (TE, 2.43 ms; TR, 15 ms; flip angle 20°; 5 slices; slice thickness 0.5 mm; matrix size, 128×128; FOV, 35×35 mm; temporal resolution 16 s; total duration 15 minutes). The change in signal intensity induced by contrast agent was calculated by subtracting the mean signal from the first 5 frames from the acquisition.
Signal intensity was converted to gadolinium concentration, via the change in longitudinal relaxation rate R1 and contrast agent relaxivity (c1 fixed at 2.9 mM -1 s
:
R1(t) was estimated from the theoretical change in spoiled gradient-echo signal magnitude.
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R10 was the mean, pre-enhancement R1, which was estimated from a Look-Locker multiinversion time acqusition, 56 acquired prior to the dyunamic sequence (TE, 1.18 ms; inversion time spacing, 110 ms; first inversion time, 2.3 ms; 50 inversion recovery readouts).
Contrast agent uptake data were fitted to a phenomenological model of the form ( ) = ( − − ( − ) ) − ( − ) [17] where S0, r1, r2 and t0 were fitted parameters. Fitting was performed in Python 2.7 (leastsq algorithm from the scipy package).
Arterial spin labelling MRI
We acquired arterial spin labeling (ASL) data with a flow-sensitive alternating inversion recovery (FAIR) Look-Locker ASL sequence, with a single-slice spoiled gradient echo readout (echo time, 1.18 ms; inversion time spacing, 110 ms; first inversion time, 2.3 ms; 50 inversion recovery readouts; 4 averages). 9, 56 Regional perfusion maps were calculated as described by
Belle et al. (38) , with an assumed blood-partition constant of 0.9.
Statistics
Differences between groups were tested for significance with the non-parametric Wilcoxon rank sum test (Python 2.7, scikit package). P < 0.05 was considered significant. All summary data are presented as mean  SD.
